StockNews.com Begins Coverage on Dynavax Technologies (NASDAQ:DVAX)

StockNews.com started coverage on shares of Dynavax Technologies (NASDAQ:DVAX – Get Rating) in a research report report published on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on DVAX. JMP Securities lifted their price target on shares of Dynavax Technologies from $22.00 to $25.00 and gave the company a market outperform rating in a research note on Friday, February 24th. HC Wainwright decreased their target price on Dynavax Technologies from $28.00 to $27.00 and set a buy rating for the company in a research report on Friday, February 24th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $24.33.

Dynavax Technologies Price Performance

DVAX stock opened at $9.44 on Thursday. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of 4.79 and a beta of 1.45. The company has a quick ratio of 5.71, a current ratio of 6.11 and a debt-to-equity ratio of 0.38. Dynavax Technologies has a 12-month low of $7.26 and a 12-month high of $17.48. The company’s fifty day simple moving average is $10.88 and its 200 day simple moving average is $11.21.

Insider Buying and Selling at Dynavax Technologies

In other news, CAO Justin Burgess sold 22,371 shares of the business’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $10.38, for a total transaction of $232,210.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.31% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

Hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. lifted its holdings in shares of Dynavax Technologies by 4.7% in the first quarter. American Century Companies Inc. now owns 86,892 shares of the biopharmaceutical company’s stock valued at $942,000 after purchasing an additional 3,902 shares in the last quarter. HighTower Advisors LLC purchased a new position in Dynavax Technologies during the 1st quarter worth $159,000. MetLife Investment Management LLC grew its stake in shares of Dynavax Technologies by 57.4% in the 1st quarter. MetLife Investment Management LLC now owns 57,543 shares of the biopharmaceutical company’s stock worth $624,000 after acquiring an additional 20,984 shares in the last quarter. Allianz Asset Management GmbH raised its holdings in shares of Dynavax Technologies by 16.8% in the first quarter. Allianz Asset Management GmbH now owns 59,070 shares of the biopharmaceutical company’s stock valued at $640,000 after purchasing an additional 8,500 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of Dynavax Technologies by 25.6% in the first quarter. Mackenzie Financial Corp now owns 16,190 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 3,300 shares during the last quarter. Institutional investors and hedge funds own 94.26% of the company’s stock.

About Dynavax Technologies

(Get Rating)

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.